Cybin

HELP · AEQUITAS

$10.19−$0.31 (−2.95%)TodayMarket closed · Oct 23, 7:58 PM ET

Prev close $10.50

Latest news

Press releaseOct 21, 4:10 PM ETGlobe Newswire
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Press releaseOct 15, 7:30 AM ETGlobe Newswire
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Press releaseOct 8, 7:30 AM ETGlobe Newswire
Helus Pharma to Host Investor Presentation on October 21, 2026
Press releaseOct 1, 7:30 AM ETGlobe Newswire
Helus Pharma Announces Completion of Legal Name Change
Press releaseSep 22, 5:00 PM ETGlobe Newswire
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
Press releaseSep 21, 5:15 PM ETGlobe Newswire
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Press releaseSep 21, 7:30 AM ETGlobe Newswire
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
NewsSep 18, 4:25 AM ETAvi Kapoor
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Press releaseSep 10, 7:30 AM ETGlobe Newswire
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
Press releaseSep 9, 7:30 AM ETGlobe Newswire
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
Press releaseSep 3, 7:30 AM ETGlobe Newswire
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
Press releaseAug 18, 7:30 AM ETGlobe Newswire
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
Press releaseAug 14, 7:28 AM ETGlobe Newswire
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Press releaseAug 10, 12:00 PM ETGlobe Newswire
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
NewsAug 10, 8:02 AM ETAvi Kapoor
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Press releaseAug 5, 10:25 AM ETGlobe Newswire
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Press releaseAug 3, 7:40 AM ETGlobe Newswire
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
NewsJul 21, 2:18 PM ETAvi Kapoor
Crude Oil Surges 2%; 3M Shares Gain After Q2 Results
Press releaseJul 21, 10:54 AM ETPRNewswire
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
NewsJul 21, 10:37 AM ETAvi Kapoor
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday
Press releaseJul 21, 9:00 AM ETPRNewswire
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Press releaseJul 21, 8:30 AM ETPRNewswire
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Press releaseJul 21, 7:50 AM ETGlobe Newswire
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Press releaseJul 17, 8:50 AM ETPRNewswire
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
NewsJul 16, 10:11 AM ETAvi Kapoor
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
NewsJul 16, 4:25 AM ETAvi Kapoor
Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Press releaseJun 30, 9:00 AM ETGlobe Newswire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Press releaseJun 29, 7:40 AM ETGlobe Newswire
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Press releaseJun 26, 9:30 AM ETPRNewswire
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
NewsJun 25, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseJun 25, 9:27 AM ETGlobe Newswire
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
NewsJun 24, 6:06 AM ET
Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment
Press releaseJun 24, 6:01 AM ETGlobe Newswire
Helus Pharma™ Announces US$50 Million Underwritten Offering
NewsMar 5, 12:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026

Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors

Helus Pharma to Host Investor Presentation on October 21, 2026

Helus Pharma Announces Completion of Legal Name Change

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Crude Oil Surges 2%; 3M Shares Gain After Q2 Results

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On Tuesday

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday

Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

12 Health Care Stocks Moving In Thursday's Intraday Session

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma Prices Underwritten Offering Of 10.3M Shares At $4.85 Per Share; Announces That Enrollment In The APPROACH Phase 3 Clinical Trial Of HLP003 For Adjunctive Treatment Of Major Depressive Disorder Is Progressing As Planned, Surpassing 86% Enrollment

Helus Pharma™ Announces US$50 Million Underwritten Offering

12 Health Care Stocks Moving In Thursday's Intraday Session